CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations

Anchit Khanna, Jayant K Rane, Kati K Kivinummi, Alfonso Urbanucci, Merja A Helenius, Teemu T Tolonen, Outi R Saramäki, Leena Latonen, Visa Manni, John E Pimanda, Norman J Maitland, Jukka Westermarck, Tapio Visakorpi

Research output: Contribution to journalArticlepeer-review


Residual androgen receptor (AR)-signaling and presence of cancer stem-like cells (SCs) are the two emerging paradigms for clinically challenging castration-resistant prostate cancer (CRPC). Therefore, identification of AR-target proteins that are also overexpressed in the cancer SC population would be an attractive therapeutic approach.Our analysis of over three hundred clinical samples and patient-derived prostate epithelial cultures (PPECs), revealed Cancerous inhibitor of protein phosphatase 2A (CIP2A) as one such target. CIP2A is significantly overexpressed in both hormone-naïve prostate cancer (HN-PC) and CRPC patients . CIP2A is also overexpressed, by 3- and 30-fold, in HN-PC and CRPC SCs respectively. In vivo binding of the AR to the intronic region of CIP2A and its functionality in the AR-moderate and AR-high expressing LNCaP cell-model systems is also demonstrated. Further, we show that AR positively regulates CIP2A expression, both at the mRNA and protein level. Finally, CIP2A depletion reduced cell viability and colony forming efficiency of AR-independent PPECs as well as AR-responsive LNCaP cells, in which anchorage-independent growth is also impaired.These findings identify CIP2A as a common denominator for AR-signaling and cancer SC functionality, highlighting its potential therapeutic significance in the most clinically challenging prostate pathology: castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)19661-19670
Number of pages10
Issue number23
Publication statusPublished - 19 Apr 2015

Cite this